GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Allergan, Inc. (AGN) [hlAlert]

Rating:
Mkt Outperform
AGN
up 185.40 %

Allergan, Inc. (AGN) upgraded to Mkt Outperform by JMP Securities

Posted on: Wednesday,  Feb 6, 2013  8:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Allergan, Inc. (NYSE: AGN) on 02/06/2013, when the stock price was $107.21.
Since then, Allergan, Inc. has gained 185.40% as of 11/24/2015's recent price of $305.98.
If you would have followed this JMP Securities's recommendation on AGN, you would have gained 185.4% of your investment in 1021 days.

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company is engaged in discovering, developing and commercializing specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. In January 2007, the Company completed the acquisition of Groupe Corneal Laboratoires (Corneal). In October 2007, the Company completed the acquisition of Esprit Pharma Holding Company, Inc. (Esprit). In July 2008, the Company acquired the Aczone (dapsone) gel 5% from QLT USA, Inc. (QLT), a wholly owned subsidiary of QLT Inc. The Company operates in two business segments: specialty pharmaceuticals and medical devices.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/6/2013 8:25 AM Buy
None
107.21
as of 12/13/2013
1 Week down  -1.65 %
1 Month up  1.86 %
3 Months up  8.78 %
1 YTD down  -9.92 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/5/2011 10:25 AM Hold
None
80.12

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy